Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700329 | 0.85 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL6704025 | 0.82 | SCD (0.44) | SMN1; SMN2S1PR3SCDPTGER4MAPT | |
| SCHEMBL6696647 | 0.77 | CLPP (0.35) | — | |
| SCHEMBL6700327 | 0.75 | CLPP (0.43) | S1PR3SCDALDH1A1PTGER4 | |
| SCHEMBL6696562 | 0.75 | PTGER4 (0.42) | S1PR3SCDPTGER4 | |
| SCHEMBL6292753 | 0.74 | MAPT (0.42) | SMN1; SMN2KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL6292786 | 0.72 | KDM4E (0.51) | SMN1; SMN2KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL6701930 | 0.72 | TRPA1 (0.54) | SMN1; SMN2RXFP1S1PR3PTGER4MAPT | |
| SCHEMBL6697984 | 0.71 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL6702369 | 0.70 | KDM4E (0.46) | SMN1; SMN2KDM4EMEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | SMN1; SMN2 3684/4885KDM4E 1991/4885MEN1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.